Nuformix plc (LON:NFX – Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00), with a volume of 24806354 shares trading hands. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Performance
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The stock’s 50-day moving average price is GBX 0.15 and its 200 day moving average price is GBX 0.18. The firm has a market cap of £491,586.00, a P/E ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- Russell 2000 Index, How Investors Use it For Profitable Trading
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Are Penny Stocks a Good Fit for Your Portfolio?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Trading Stocks: RSI and Why it’s Useful
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
